Open Access iconOpen Access

ARTICLE

crossmark

CES1 is associated with cisplatin resistance and poor prognosis of head and neck squamous cell carcinoma

by CHUAN JIANG1,2, CHUNLEI LIU1,3, XI YAO1,3, JINGYA SU1,2, WEI LU1,3, ZHENGBO WEI3,*, YING XIE1,2,*

1 Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry ofEducation, Nanning, 530000, China
2 Life Sciences Institute, Guangxi Medical University, Nanning, 530000, China
3 Department of Head and Neck Tumor Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, 530000, China

* Corresponding Authors: ZHENGBO WEI. Email: email; YING XIE. Email: email

Oncology Research 2024, 32(12), 1935-1948. https://doi.org/10.32604/or.2024.052244

Abstract

Background: Head and neck squamous cell carcinoma (HNSCC) is a prevalent form of cancer globally, with chemoresistance posing a major challenge in treatment outcomes. The efficacy of the commonly used chemotherapeutic agent, cisplatin, is diminished in patients with poor prognoses. Methods: Various bioinformatics databases were utilized to examine Carboxylesterase 1 (CES1) gene expression, clinicopathologic features, patient survival analysis, and gene function. An organoid model of HNSCC was established, along with the induction of drug-resistant HNSCC in the organoid model. CES1 expression was assessed using qRT-PCR and Western Blot, and differential markers were identified through transcriptome sequencing. Knockdown and overexpression models of CES1 were created in SCC-9 and patient-derived organoid (PDO) cells using shRNA and lentivirus to investigate the tumor biology and cisplatin resistance associated with CES1. Results: Research in bioinformatics has uncovered a strong correlation between the expression level of CES1 and the prognosis of HNSCC. The data suggests a significant link between CES1 expression and tobacco smoking. RNA-sequencing revealed a notable increase in CES1 expression in HNSCC-PDOcis-R cells compared to the parental PDO cells. Subsequently, we performed in vitro studies by HNSCC-PDO and SCC-9 and found that CES1-overexpressing cells exhibited reduced sensitivity to cisplatin and stronger tumor malignant biological behavior compared with CES1-knockdown cells. Conclusion: The observed association between CES1 expression and tobacco smoking implies a potential influence of smoking on the efficacy of cisplatin-based chemotherapy in HNSCC through the regulation of CES1 expression.

Keywords


Cite This Article

APA Style
JIANG, C., LIU, C., YAO, X., SU, J., LU, W. et al. (2024). CES1 is associated with cisplatin resistance and poor prognosis of head and neck squamous cell carcinoma. Oncology Research, 32(12), 1935-1948. https://doi.org/10.32604/or.2024.052244
Vancouver Style
JIANG C, LIU C, YAO X, SU J, LU W, WEI Z, et al. CES1 is associated with cisplatin resistance and poor prognosis of head and neck squamous cell carcinoma. Oncol Res. 2024;32(12):1935-1948 https://doi.org/10.32604/or.2024.052244
IEEE Style
C. JIANG et al., “CES1 is associated with cisplatin resistance and poor prognosis of head and neck squamous cell carcinoma,” Oncol. Res., vol. 32, no. 12, pp. 1935-1948, 2024. https://doi.org/10.32604/or.2024.052244



cc Copyright © 2024 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 943

    View

  • 152

    Download

  • 0

    Like

Share Link